Guidewire Announces 2019.1 Release of P&C Insurance Industry Platform to Accelerate Insurer Growth
7.5.2019 23:55:00 EEST | Business Wire | Press release
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the 2019.1 release of Guidewire InsurancePlatform™. This latest release supports insurers’ imperatives to optimize operations, be more digital, use data in new ways, and innovate quickly. Underlying these business drivers is a general theme to simplify and de-risk insurers’ IT environments.
“Insurers today are driving towards more continuous delivery of technology enabled capabilities to their internal and external stakeholders. Increased release cadence of vended core systems like Guidewire InsurancePlatform, will help insurers address increasing time to market demands and improved upgrade experience,” said Martina Conlon, executive vice president, Research and Consulting and practice leader for property/casualty at Novarica.
Guidewire InsurancePlatform has been designed to power the P&C insurance business, in support of the following key insurer imperatives:
Use data in new ways: InsurancePlatform helps insurers drive smart decisions across the insurance lifecycle by leveraging scientific techniques and delivering actionable insights at the time key decisions are being made:
- New innovations in Guidewire Predictive Analytics™ make it easier to import and operationalize models built with third-party software, prevent overfitting of certain variables, allow for gradual adoption of model recommendation, and monitor overall impact on claims, pricing, and submissions.
Improve digital engagement: To meet rising digital expectations, InsurancePlatform 2019.1 helps insurers increase digital engagement by digitizing every interaction and delivering a satisfying, consumer grade, omnichannel experience.
- Provides more streamlined quoting experiences for customers, agents, brokers, and customer service representatives (CSRs) through enhanced quote flow navigation that enables users to move back and forth in quote flows while maintaining the integrity of the data submitted, thus improving the speed and efficiency of the quoting process.
- Innovative error handling in Guidewire ProducerEngage™ and Guidewire ServiceRepEngage™ notifies agents, brokers, and CSRs of data entry errors and qualification issues as they occur, allowing them to address issues right away to save time and avoid working on quotes that cannot be bound. The alerts fall into three categories: error messages, warnings, and underwriting approval alerts.
Innovate quickly: To empower insurers to respond to changing competition and new entrants, InsurancePlatform enables innovation while reducing complexity of integrations with promising insurtechs as well as established players.
- Insurers can choose from 100 Guidewire validated third party solution integrations currently available for download in the Guidewire Marketplace.
- Guidewire PartnerConnect™ Solution partners added since the October 2018 release include: ACI Worldwide, Advanced Remarketing Services, Franco Signor, Mirror Technologies, Omadi, Ontellus, TruePic, and Zipwhip.
- In the past four months, 7 Solution Partners have signed up to use the new Guidewire DevConnect™ developer environment to create plug and play Ready for Guidewire add-ons for ClaimCenter: Advanced Remarketing Services, Livegenic, Mirror Technologies, Omadi, Ontellus, TruePic and WeGoLook.
Simplify IT complexity: InsurancePlatform reduces IT complexity and minimizes the operational burden with key infrastructure improvements to InsuranceSuite.
- The Policy Migration Tool reduces the cost and risk associated with legacy policy migration into Guidewire PolicyCenter™ by providing a supported tool that simplifies the process.
- The InsuranceSuite Behavior Testing Framework promotes better collaboration between business and IT by enabling business analysts to create InsuranceSuite test scenarios in everyday language.
“InsurancePlatform releases remain focused on simplifying the technology that supports insurers, while improving digital engagement across the customer lifecycle, enabling insurers to achieve their business imperatives,” said Ayan Sarkar, principal, InsurancePlatform, Guidewire. “2019.1 unveils exciting new products, features, and tools in support of these objectives.”
Guidewire InsuranceSuite™ has been positioned as a Leader in Gartner’s Magic Quadrant for P&C Core Platforms, North America1. Guidewire Software has also been positioned as a Leader in Gartner’s Magic Quadrant for Non-Life-Insurance Platforms, Europe2.
Note that not all products are available in every geography. Guidewire customers can get more information from their Account Executive.
1 Gartner, Magic Quadrant for P&C Core Platforms, North America, Jeff Haner, October 9, 2018
2 Gartner, Magic Quadrant for Non-Life Insurance Platforms, Europe, Sham Gill, 26 November 2018
Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Guidewire Software
Guidewire delivers the industry platform that Property and Casualty (P&C) insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and partner ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 companies in 32 countries. For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: All products mentioned in this announcement are Guidewire products. For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507006111/en/
Contact information
Diana Stott
Director, Communications
Guidewire Software
+1
650-356-4941
dstott@guidewire.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom